The upcoming webinar, hosted by Xtalks on September 29, 2026, shifts the focus from merely suppressing the placebo response to implementing a signal intelligence framework. By analyzing participant, rater, site, and study-level data, trial teams can better distinguish meaningful therapeutic effects from the background noise inherent in current measurement tools.

Luka Lucić, PhD, and Svenja Wacker, PhD, from Cogstate will lead the session, detailing how trial teams can assess clinical coherence and apply targeted interventions. The discussion aims to equip professionals with strategies to identify risks to endpoint quality and strengthen the ability to measure authentic change in MDD patients.